AstraZeneca PLC on Monday mentioned its most cancers drug Enhertu has proven clinically significant and sturdy responses throughout a number of HER2-expressing superior strong tumors in its DESTINY-PanTumor02 Part II trial.
The Anglo-Swedish pharma main
AZN,
AZN,
mentioned Enhertu–trastuzumab deruxtecan, which it’s collectively growing and commercializing with Daiichi Sankyo–had met prespecified standards for goal response fee and length of response.
“Enhertu has already demonstrated its potential to enhance outcomes for sufferers with HER2-targetable breast, gastric and lung cancers, and these constructive preliminary leads to different tumor settings with important unmet want are very encouraging,” mentioned Chief Medical Officer and Oncology Chief Improvement Officer Cristian Massacesi.
Write to Elena Vardon at elena.vardon@wsj.com